Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Recruiting · NCT03855917 · Registry updated 2026-07-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir | Blood-Borne Infections, Digestive System Diseases, Flaviviridae infectious disease, Infections, RNA Virus Infections, hepatitis, hepatitis C virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 4 | 2026-07-29 | NCT03855917 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kirby Institute | 19 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Blacktown Mt Druitt Hospital | Sydney | Australia | 1 |
| Royal Adelaide Hospital | Adelaide | Australia | 132 |
| St Vincent's Hospital | Darlinghurst | Australia | 9 |